中红医疗
(300981)
| 流通市值：12.97亿 | | | 总市值：41.18亿 |
| 流通股本：1.23亿 | | | 总股本：3.90亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,581,745,922.68 | 998,882,650.75 | 431,749,545.61 | 1,572,568,513.46 |
| 营业收入 | 1,581,745,922.68 | 998,882,650.75 | 431,749,545.61 | 1,572,568,513.46 |
| 二、营业总成本 | 1,537,141,757.31 | 968,977,169 | 453,712,775.31 | 1,522,755,355.88 |
| 营业成本 | 1,383,388,167.53 | 887,877,135.35 | 398,233,384.21 | 1,420,088,044.4 |
| 税金及附加 | 15,219,471.33 | 10,758,116.74 | 3,614,871.36 | 20,156,552.57 |
| 销售费用 | 81,550,542.21 | 53,188,088.48 | 19,598,276.87 | 56,000,659.69 |
| 管理费用 | 77,104,491.39 | 41,919,522.7 | 24,522,246.65 | 78,962,786.43 |
| 研发费用 | 24,136,595.38 | 14,102,638.36 | 5,288,254.19 | 8,832,173.18 |
| 财务费用 | -44,257,510.53 | -38,868,332.63 | 2,455,742.02 | -61,284,860.39 |
| 其中:利息费用 | 11,336,004.31 | 6,504,655.44 | 2,116,942.56 | 1,661,620.96 |
| 其中:利息收入 | 31,190,153.73 | 18,921,458.55 | 8,456,107.42 | 28,697,117.42 |
| 加:公允价值变动收益 | 41,980,258.9 | 27,349,315.13 | 26,281,577.03 | 51,458,139.85 |
| 加:投资收益 | 12,420,276.75 | 10,366,953.31 | 4,097,610.88 | 14,238,438.38 |
| 资产处置收益 | -83,971.26 | -108,583.62 | -6,632.48 | 431,828.02 |
| 资产减值损失(新) | -113,383,790.16 | -86,927,479.2 | -34,872,550.04 | -143,685,999.64 |
| 信用减值损失(新) | 6,564,473.85 | 2,642,925.28 | 6,436,856.4 | -6,327,706.25 |
| 其他收益 | 17,635,598.83 | 13,581,121.09 | 11,342,129.54 | 23,076,715.09 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 9,737,012.28 | -3,190,266.26 | -8,684,238.37 | -10,995,426.97 |
| 加:营业外收入 | 41,820.11 | 39,813.57 | 172,977.29 | 65,243,774.55 |
| 减:营业外支出 | 1,221,881.3 | 531,447.1 | 73,060.63 | 2,976,768.94 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 8,556,951.09 | -3,681,899.79 | -8,584,321.71 | 51,271,578.64 |
| 减:所得税费用 | -1,091,165.99 | -3,079,436.1 | -4,223,093.29 | -15,710,501.23 |
| 六、净利润 | 9,648,117.08 | -602,463.69 | -4,361,228.42 | 66,982,079.87 |
| 持续经营净利润 | 9,648,117.08 | -602,463.69 | -4,361,228.42 | 66,982,079.87 |
| 归属于母公司股东的净利润 | 9,197,195.77 | -4,942,596.19 | -6,174,718.09 | 66,916,009.08 |
| 少数股东损益 | 450,921.31 | 4,340,132.5 | 1,813,489.67 | 66,070.79 |
| (一)基本每股收益 | 0.02 | -0.01 | -0.02 | 0.22 |
| (二)稀释每股收益 | 0.02 | -0.01 | -0.02 | 0.22 |
| 八、其他综合收益 | 2,791,206.18 | 2,117,454.54 | 494,373.56 | -1,689,545.42 |
| 归属于母公司股东的其他综合收益 | 2,791,206.18 | 2,117,454.54 | 494,373.56 | -1,689,545.42 |
| 九、综合收益总额 | 12,439,323.26 | 1,514,990.85 | -3,866,854.86 | 65,292,534.45 |
| 归属于母公司股东的综合收益总额 | 11,988,401.95 | -2,825,141.65 | -5,680,344.53 | 65,226,463.66 |
| 归属于少数股东的综合收益总额 | 450,921.31 | 4,340,132.5 | 1,813,489.67 | 66,070.79 |
| 公告日期 | 2023-10-25 | 2023-08-30 | 2023-04-25 | 2023-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |